Oras Alabas

Oras Alabas serves as a Research Associate in the Division of Musculoskeletal & Dermatological Sciences, specializing in statistical analysis for the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). This drug safety registry evaluates long-term treatment outcomes for psoriasis patients in real-world clinical settings.

Education:

• Doctor of Philosophy

His research focuses on advanced statistical methodologies including survival analysis, mixed multilevel modeling, and structural modeling applied to dermatological epidemiology. He investigates drug safety profiles, treatment response predictors, and real-world utilization patterns of biologic therapies for moderate-to-severe psoriasis, with particular emphasis on cohort study designs and pharmacovigilance.

Recent publications demonstrate consistent application of sophisticated statistical techniques to BADBIR registry data, revealing critical insights about IL-23/IL-17 inhibitor performance, age-related treatment outcomes, and combination therapy safety. His work bridges clinical dermatology with quantitative methodology to optimize biologic treatment strategies.

Alabas actively collaborates within the international BADBIR Study Group, contributing to evidence-based dermatological practice. His research directly supports UN Sustainable Development Goal 3 (Good Health and Well-being) through pharmacovigilance and treatment optimization for chronic skin conditions.